Atara Biotherapeutics Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
ATRA$8.10-1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
(In thousands, except per share amounts)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Commercialization revenue | $27,357 | $884 |
| License and collaboration revenue | — | 342 |
| Total revenue | 27,357 | 1,226 |
| Costs and operating expenses: | ||
| Cost of commercialization revenue | 1,985 | 216 |
| Research and development expenses | 45,506 | 62,156 |
| General and administrative expenses | 11,113 | 13,872 |
| Total costs and operating expenses | 58,604 | 76,244 |
| Loss from operations | (31,247) | (75,018) |
| Other income (expense), net: | ||
| Interest income | 604 | 1,802 |
| Interest expense | (1,153) | (1,336) |
| Other income (expense), net | 68 | (197) |
| Total other income (expense), net | (481) | 269 |
| Loss before provision for (benefit from) income taxes | (31,728) | (74,749) |
| Provision for (benefit from) income taxes | 24 | 22 |
| Net income (loss) | $(31,752) | $(74,771) |
| Other comprehensive gain (loss): | ||
| Unrealized gain (loss) on available-for-sale securities | 149 | 830 |
| Comprehensive income (loss) | $(31,603) | $(73,941) |
| Basic and diluted net loss per common share | $(0.23) | $(0.72) |
| Basic and diluted weighted-average shares outstanding | 140,587 | 103,969 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.